| Indication | Hematological malignancies |
| Drug | OTX015 |
| Mechanism of Action | BET inhibitor |
| Company | Merck |
| Trial Phase | Phase 1b |
| Category | Corporate & Strategic |
| Sub Category | Acquisition Announced |
| Therapeutic Area | Oncology |
| Acquired Company | OncoEthix |
| Deal Type | Acquisition |
| Upfront Payment | $110 million |
| Milestone Payments | $265 million |
| Target Proteins | BET bromodomain proteins 2/3/4 |
| Patient Population | Patients with hematological malignancies, advanced solid tumors |
| Conference Presentation | American Association of Cancer Research (AACR) Annual Meeting |
| Presentation Date | April 2014 |
| Drug In-licensed From | Mitsubishi Tanabe Pharma Corporation |
| In-licensing Date | March 2012 |
Merck Acquires OncoEthix, Expands Oncology Pipeline
Merck announced the acquisition of OncoEthix, a Swiss-based oncology company, to expand its oncology portfolio with OTX015, a novel oral BET inhibitor. OTX015 is currently in Phase 1b studies for hematological malignancies and advanced solid tumors, having shown promising early clinical activity. The deal includes an upfront payment of up to $110 million and potential milestone payments of up to $265 million, reinforcing Merck's commitment to developing innovative cancer therapies.
- Merck's acquisition of OncoEthix is a strategic move to bolster its oncology pipeline with OTX015, a potential first-in-class oral BET inhibitor. This aligns with Merck's focus on developing innovative molecules for advanced cancers and complements its broad immuno-oncology development program, enhancing its presence in a priority therapeutic area.
- OTX015 is an investigational orally administered synthetic small molecule targeting BET bromodomain proteins 2/3/4. It is currently in Phase 1b clinical studies for hematological malignancies and advanced solid tumors, with interim data presented at AACR 2014 demonstrating meaningful clinical activity in hematological cancers.
- The financial structure of the acquisition includes an upfront payment of up to $110 million to OncoEthix, with additional milestone payments of up to $265 million contingent upon clinical and regulatory achievements. OncoEthix, founded in 2009, in-licensed OTX015 from Mitsubishi Tanabe Pharma Corporation in March 2012 after initial Phase I studies.
Unlocking Cancer Growth: The Role of BET Proteins
Multiple hematologic malignancies are initiated by defining genetic lesions that cooperate with secondary mutations to drive clonal evolution. These include the t(15;17)(q22;q11.2) chromosomal translocation creating the promyelocytic leukemia-retinoic acid receptor α (PML-RARA) fusion oncogene with cooperating Jak1 V657F, identical to the JAK1 V658F mutation previously found in human APL, and somatic 150-kb deletion involving the lysine (K)-specific demethylase 6A (Kdm6a, also known as Utx) gene, as well as BCR-ABL1 fusion protein from t(9;22)(q34;q11) in chronic myelogenous leukemia, MLL-AF4+ rearrangement in infant ALL, and IDH1 mutations p.R132H, p.R132C, p.R132S, p.R132G, p.R132L and p.I99M and IDH2 mutations p.R140Q and p.R172K with coexisting NPM1 mutations (60-74%). At presentation myeloma is composed of two to six different major clones related by linear and branching phylogenies, with parallel evolution whereby two independent clones activate the RAS/MAPK pathway through RAS mutations, co-occurrence of RAS and interferon regulatory factor 4 (IRF4) p.K123R mutations in 4% of myeloma patients, and progression patterns described as a "static progression model" where subclonal architecture is retained and a "spontaneous evolution model" where change in subclonal composition is observed. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1 ALL by enhancing genetic instability and aberrant somatic hypermutation and by negative regulation of tumor-suppressor genes including Rhoh, Cdkn1a (p21), and Blnk (SLP65), with AID(-/-) leukemia showing lower frequency of amplifications and deletions and lower frequency of mutations in non-Ig genes including Pax5 and Rhoh, while progression from smoldering stages is driven by APOBEC cytidine deaminases and T-ALL relapse involves drivers MDR1 and MVP, NT5C2 and JAK-STAT activators, IL7R upregulation in type-1 relapse, and BLM, BUB1B/PMS2 and TP53 mutations with hypermutator phenotypes in type-2 relapse.
Epigenetic and transcriptional dysregulation further controls differentiation, proliferation, apoptosis, and malignant transformation. Gene transcriptional activity is regulated by chromatin modification and DNA methylation, with nuclear receptors such as RAR, RXR, and PPARgamma exerting histone acetyl transferase activity (HAT), and histone acetylation by the PPARgamma agonist CDDO, RAR/RXR agonist ATRA, and/or histone deacetylase inhibitors (HDACIs) reversing silenced RARbeta and MDR1 genes in acute promyelocytic leukemia. In HTLV-1-transformed CD4+ T cells, HTLV-1 Tax-induced promoter silencing causes dissociation of Sp1, Oct-1, NF-kappaB, CREB-1, and RNA polymerase II from the core SHP-1 P2 promoter with heavy CpG methylation and decreased expression of the Src homology-2-containing protein-tyrosine phosphatase 1 (SHP-1), a negative regulator of cell signaling considered a tumor suppressor gene for its ability to antagonize tyrosine kinases. Histone modification also mediates response to FK228 (depsipeptide) (0.2-1 ng/mL) through time- and dose-dependent histone H4 hyper-acetylation or histone H3 dephosphorylation and alterations in DNA binding of NF-kappaB, with p53 binding to the p21 (Waf1/Cip1) promotor and induction of Annexin A1 in AML1/ETO-positive acute myelocytic leukemia cells.
The bone marrow microenvironment and leukemia-initiating cell hierarchies sustain persistence, immune evasion, and therapy resistance. Growth factors and integrins interact with receptors and activate signaling cascades with intimate interconnections, with therapeutic interventions focusing on SDF1/CXCR4, ILK/PI3K/Akt, TGF-beta, and Notch signaling, and specific niches within the bone marrow microenvironment providing sanctuary for subpopulations of leukemic cells to escape chemotherapy-induced death and acquire drug resistance. Multiple myeloma originates from the B cell lineage with memory-B cell like features allowing self-renewal and differentiation to monoclonal plasma cells, using signaling pathways and microenvironment similar to the hematopoietic stem cell and inducing quiescence through direct interaction with stroma, with a median of 6 tumor subclones per patient, unique subclones in focal lesions, differential expression of CD20 and CD38, depletion of macrophages in focal lesions, and fluctuations revealing clonal extinction and emergence of new clones. Mature B lymphocytes demonstrate lineage plasticity exemplified by transdifferentiation of follicular lymphomas into clonally related Langerhans cell sarcoma and Langerhans cell histiocytosis, while MLL-AF4+ infant ALL shows dynamic competition between actively proliferating and quiescent subclones with relapses often occurring from subclones already present but more quiescent at diagnosis, and BCR-ABL1 kinase domain mutations including T315I abrogating imatinib binding and rendering leukemia resistant to first- and second-line TKIs.
OTX015's Broad Clinical Potential Across Hematological and Solid Tumors
OTX015 (birabresib/MK-8628), a first-in-class bromodomain inhibitor binding BRD2, BRD3, and BRD4, was evaluated beyond hematologic tumors in a phase Ib study in selected advanced solid tumors. Safety, efficacy, and pharmacokinetics of birabresib were evaluated in patients with castrate-resistant prostate cancer, nuclear protein in testis midline carcinoma (NMC), and non-small-cell lung cancer.
Trial population in solid tumors: Of 46 treated patients, 26 had castrate-resistant prostate cancer, 10 had NMC, and 10 had non-small-cell lung cancer, from 47 patients enrolled.
Intervention model with parallel dose escalation: Patients received birabresib once daily at starting doses of 80 mg continuously (cohort A) or 100 mg for 7 consecutive days (cohort B) in 21-day cycles using a parallel dose escalation 3 + 3 design, with occurrence of dose-limiting toxicities (DLTs) and determination of the recommended phase II dose as the primary objective.
Recommended dosing and activity signal: The recommended phase II dose of birabresib in patients with select solid tumors is 80 mg once daily with continuous dosing, with dose-proportional increase in birabresib exposure and rapid absorption; three patients with NMC (80 mg once daily) had a partial response (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) with duration of 1.4 to 8.4 months.
Additional solid-tumor evaluation: OTX015 is under evaluation in dose-finding studies in solid tumors, including GBM, supporting the rationale for the OTX015 Phase Ib (NCT02259114) in solid tumors, where NSCLC patients with rearranged ALK gene or KRAS-positive mutations are currently being treated.
Frequently Asked Questions
References
- [1] Richter-Pechańska P, Kunz JB et al.. Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. Leukemia. 2022 Jul. 35585141
- [2] Lewin J, Soria JC et al.. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Oct 20. 29733771
- [3] Chotirat S, Thongnoppakhun W et al.. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Journal of hematology & oncology. 2012 Mar 7. 22397365
- [4] Melchor L, Brioli A et al.. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014 Aug. 24480973
- [5] Suguna E, Farhana R et al.. Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach. Cardiovascular & hematological disorders drug targets. 2018. 29766829
- [6] Savickiene J, Treigyte G et al.. The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation. Annals of the New York Academy of Sciences. 2006 Dec. 17341629
- [7] Tabe Y. [Molecular diagnosis of and molecular targeting therapy for leukemia]. Rinsho byori. The Japanese journal of clinical pathology. 2009 Feb. 19317219
- [8] Chen D, Lu T et al.. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins. European journal of medicinal chemistry. 2019 Nov 15. 31461688
- [9] Bardini M, Woll PS et al.. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia. 2015 Jan. 24798483
- [10] Boi M, Gaudio E et al.. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 1. 25623213
- [11] Wartman LD, Larson DE et al.. Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. The Journal of clinical investigation. 2011 Apr. 21436584
- [12] Nakase K, Cheng J et al.. Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. Journal of leukocyte biology. 2009 Jan. 18948549
- [13] Khoury R, Raffoul C et al.. Precision Medicine in Hematologic Malignancies: Evolving Concepts and Clinical Applications. Biomedicines. 2025 Jul 7. 40722725
- [14] Riveiro ME, Astorgues-Xerri L et al.. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget. 2016 Dec 20. 27835869
- [15] Annereau M, Legrand FX et al.. Hospital-Compounded Birabresib Capsules for NUT Carcinoma: A Quality- and Risk-Based CMC Strategy. Pharmaceutical research. 2026 May. 41882454
- [16] West DS, Dogan A et al.. Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. The American journal of surgical pathology. 2013 Jul. 23759932
- [17] Tasian SK, Bornhäuser M et al.. Targeting Leukemia Stem Cells in the Bone Marrow Niche. Biomedicines. 2018 Feb 21. 29466292
- [18] Thieblemont C, Molina T et al.. Optimizing therapy for nodal marginal zone lymphoma. Blood. 2016 Apr 28. 26989202
- [19] Yuan N, Wei W et al.. Young donor hematopoietic stem cells revitalize aged or damaged bone marrow niche by transdifferentiating into functional niche cells. Aging cell. 2023 Aug. 37226323
- [20] Kellner J, Liu B et al.. Fact or fiction--identifying the elusive multiple myeloma stem cell. Journal of hematology & oncology. 2013 Dec 7. 24314019
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com












